SANDOZ LATANOPROST/TIMOLOL SOLUTION

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

LATANOPROST; TIMOLOL (TIMOLOL MALEATE)

Inapatikana kutoka:

SANDOZ CANADA INCORPORATED

ATC kanuni:

S01ED51

INN (Jina la Kimataifa):

TIMOLOL, COMBINATIONS

Kipimo:

50MCG; 5MG

Dawa fomu:

SOLUTION

Tungo:

LATANOPROST 50MCG; TIMOLOL (TIMOLOL MALEATE) 5MG

Njia ya uendeshaji:

OPHTHALMIC

Vitengo katika mfuko:

2.5ML

Dawa ya aina:

Prescription

Eneo la matibabu:

BETA-ADRENERGIC AGENTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0248501002; AHFS:

Idhini hali ya:

CANCELLED POST MARKET

Idhini ya tarehe:

2019-04-26

Tabia za bidhaa

_Sandoz Latanoprost/Timolol _
_Page 1 of 31_
PRODUCT MONOGRAPH
PR SANDOZ LATANOPROST/TIMOLOL
Latanoprost and timolol ophthalmic solution, 50 mcg/mL / 5 mg/mL (as
timolol maleate)
Elevated Intraocular Pressure Therapy
Prostaglandin F
2α A
nalogue and Beta-adrenergic Receptor Blocker
Sandoz Canada Inc.
Date of Preparation:
145 Jules-Léger
December 28, 2017
2017
Boucherville, QC, Canada
J4B 7K8
Submission Control No: 211248
_ _
_Sandoz Latanoprost/Timolol _
_Page 2 of 31_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................14
OVERDOSAGE
................................................................................................................14
ACTION AND CLINICAL PHARMACOLOGY
............................................................15
STORAGE AND STABILITY
..........................................................................................16
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................16
PART II: SCIENTIFIC INFORMATION
...............................................................................18
PHARMACEUTICAL INFORMATION
..........................................................................18
CLINICAL TRIALS
...........